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ABSTRACT 
Quality of health care is a hot topic, especially with regard to cancer. Although rectal cancer 
is, in many aspects, a model oncologic entity, there seem to be substantial differences in 
quality of care between countries, hospitals and physicians. PROCARE, a Belgian 
multidisciplinary national project to improve outcome in all patients with rectum cancer, 
identified a set of quality of care indicators covering all aspects of the management of rectal 
cancer. This set should permit national and international benchmarking, i.e. comparing 
results from individual hospitals or teams with national and international performances with 
feedback to participating teams. Such comparison could indicate whether further 
improvement is possible and/or warranted. 
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Quality of healthcare can be defined as “the degree to which health services for individuals 
and populations increase the likelihood of desired health outcomes and are consistent with 
current professional knowledge”(1). This is a hot topic, especially for cancer care. 
Rectal carcinoma is, in many aspects, a model oncologic entity. Major milestones in rectal 
cancer treatment during the past 25 years were the introduction of total mesorectal excision 
(TME) (2) and the development of a multimodal neo-adjuvant therapy concept (3). 
Nevertheless, there seem to be substantial differences in quality of care between countries, 
hospitals and physicians (4-6). To reduce hospital variation, most initiatives aim on selective 
referral, encouraging patients to seek care in high-volume hospitals, where cancer care is 
concentrated to site-specialist multidisciplinary teams (7). There is, however, a growing 
awareness that population-based audit of cancer services is essential to ensure high quality 
cancer care: as an alternative to volume-based referral, hospitals and surgeons can also 
improve their results by learning from their own outcome statistics and those from 
colleagues treating a similar patient group.  
Although this is widely recognised, the vast majority of reports on the relation between 
quality and outcome of rectal cancer focuses on surgical outcomes mainly related to surgeon 
or hospital volume (8-10), level of surgical training (11), ethnicity or socio-economic status 
(12,13) of the patients. Those are in fact basically structural factors. The number of initiatives 
developing indicators to measure the quality of rectal cancer care taking  into account the 
whole process  from patient presentation to postoperative follow-up are scarce (14,15). 
 
PROCARE (PROject on CAncer of the REctum), a Belgian multidisciplinary national project to 
improve outcome in all patients with rectum cancer (4,16,17), has been launched in 2006. 
Guidelines were made by a multidisciplinary group (18) and are also available on the web 
(19). Decentralised implementation of guidelines was organised by the scientific and 
professional organisations. Overall quality of care is assured by registration in a specific 
national database starting in 2006. Through feedback all centres are able to position 
themselves in comparison to national indicators. The quality of care indicators cover the 
following domains: diagnosis and staging, neoadjuvant treatment, surgery, adjuvant 
treatment, palliative treatment, follow-up and histopathologic examination. Some indicators 
cover most if not all of these items, and can be considered general quality indicators. 
General quality indicators 
In this group five indicators are considered: overall survival by stage, disease-specific survival 
by stage, disease-free survival, relative survival and proportion of patients with local 
recurrence.  
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Both survival and local recurrence rate are affected by most processes of rectal cancer care 
(18). Therefore, survival, disease-free survival and local recurrence are frequently used in 
clinical studies on rectal cancer (18,20-23). 
Diagnosis and staging 
With regard to these indicators, PROCARE considers proportion of patients (a) with a 
documented distance from the anal verge, (b) in whom a CT of the abdomen and X-ray or CT 
thorax was performed before any treatment, (c) in whom a CEA was performed before any 
treatment, (d) in whom complete large bowel-imaging was performed before undergoing 
elective surgery, (e) in whom a transrectal ultrasonograpgy (TRUS) and pelvic CT and/or 
pelvic MRI were performed before any treatment and (f) with cStage II-III rectal cancer that 
have a reported cCRM (clinical circumferential resection margin). Other indicators taken into 
account are time between first histopathologic diagnosis and first treatment, accuracy of 
cM0 staging, accuracy of cT/cN staging in case of no or short radiotherapy, use of TRUS in 
cT1/cT2 stages, and use of MRI in cStage II or III. 
The distance from the lower edge of the tumour to the anal verge is an important clinical 
parameter, since it co-determines the indication for neoadjuvant treatment, the type of 
surgery and the outcome (18,24,25). The aim of imaging techniques such as CT, MRI and PET 
is to detect hepatic and extrahepatic metastatic disease (18). A combined thorax and 
abdomen/pelvis spiral contrast-enhanced CT is recommended for routine use (14). Pre-
treatment CEA levels have been related to cancer stage and survival independent of pTN 
stage in nonmetastatic colorectal cancer (18). Therefore, the serum CEA level should be 
determined in all patients before the start of any treatment (25). It is recommended that  
patients with rectal cancer undergo a total colonoscopy with resection of concomitant 
polyps if possible (18). However, if colonoscopy is judged to be too risky or if colonoscopy is 
refused, a high-quality double contrast barium enema or virtual colonoscopy should be 
performed (14,24-26). Patients with rectal cancer should have locoregional cTN staging. 
TRUS and high-resolution MRI (or CT) play an important role in the staging of rectal cancer 
(18). An important outcome of the preoperative staging is the CRM, which is a predictor of 
local and distant recurrence as well as survival (27-32). The CRM can be reliably predicted by 
preoperative high-resolution MRI (18). According to the guidelines of the Association of 
Coloproctology of Great Britain and Ireland (ACPGBI), the interval between making a 
diagnosis of cancer and the start of treatment should be less than 4 weeks (18,33). 
Neoadjuvant treatment 
In this category seven indicators are considered: proportion of cStage I patients that 
received neoadjuvant radio(chemo)therapy, proportion of cStage II-III patients (a) that 
received a neoadjuvant pelvic radiotherapy (RT), (b) treated with neoadjuvant 5-FU based 
chemoradiation that received a continuous infusion of 5-FU, (c) treated with a long course of 
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preoperative pelvic RT or chemoradiation that completed this neoadjuvant treatment within 
the planned timing and (d) treated with a long course of preoperative pelvic RT or 
chemoradiation that was operated 4 to 12 weeks after completion of the (chemo)radiation, 
the proportion of patients with cCRM < or = 2mm on MRI/CT that received long course 
neoadjuvant radio(chemo)therapy, and the rate of acute grade 4 radio(chemo)therapy-
related complications. 
Preoperative (chemo)radiation therapy has become a common practice for stage II and III 
rectal cancers (34). It has been well documented that neoadjuvant chemoradiation induces 
tumour regression and downstaging, and therefore increases tumour resectability and the 
rate of sphincter preservation (35-37). Furthermore, as shown by a large, prospective, 
randomised trial conducted by the German Rectal Cancer Study Group (3), this treatment 
modality results in a significantly reduced rate of local recurrence and treatment toxicity 
when compared with postoperative chemoradiation, while preoperative chemoradiation 
does not seem to offer survival advantage. Although many quality indicators on 
chemotherapy and radiotherapy are identified in the literature (24-26), none of these 
specifically address neoadjuvant treatment. Therefore, the PROCARE recommendations on 
neoadjuvant treatment were used as a basis to formulate additional indicators (18). 
Surgery 
The list of surgery-related quality of care indicators includes 10 items: (a) proportion of R0 
resections, (b) (y)p distal margin involved (positive) after SSO or Hartmann’s procedure for 
low rectal cancer (< or = 5cm), (c) mesorectal (y)pCRM positivity after radical surgical 
resection, (d) proportion of abdominoperineal anorectal excision (APR), Hartmann’s 
procedure or proctocolectomy with definitive ileostomy, (e) proportion of patients with 
stoma 1 year after sphincter-sparing surgery, (f) major leakage after partial mesorectal 
excision (PME) + SSO + reconstruction, (g) major leakage after TME + SSO + reconstruction 
(global, i.e. with or without primary derivative stoma), (h) inpatient or 30-day mortality, (i) 
rate of intra-operative rectal perforation and (j) postoperative major surgical morbidity 
requiring reintervention under narcosis after radical surgical resection. 
Curative resection rate is used very often as a quality indicator (14,25,26). Indeed, the main 
emphasis of surgery is to obtain clear surgical margins yielding a curative R0 resection (no 
residual tumour) (15). TME has been considered the optimal surgical modality for the 
treatment of rectal cancer since Heald et al. reported TME in 1982 (2); therefore, the 
proportion of APR and Hartmann’s procedure is considered a very important quality 
indicator (being an outcome of importance to patients) (26). Surgeons should aim, wherever 
possible and desirable, to preserve the anal sphincter (18). A temporary defunctioning stoma 
should be considered each time the anastomosis is at risk for leakage after sphincter-sparing 
surgery (18). In general, a temporary stoma is closed within 1 year after surgery, i.e. after the 
end of adjuvant chemotherapy. Inpatient or 30-day mortality is an outcome that is affected 
DEMETTER P.   
 
6
by many factors (14,18,26), such as stage, age, comorbidity, mode of surgery i.e. 
elective/scheduled vs. urgent/emergency. These factors need to be taken into account at 
risk-adjustment for appropriate interpretation of this indicator (26). Intra-operative 
perforation increases local recurrence and decreases survival; it occurs more frequently 
during APR as compared with anterior resection (18). 
Adjuvant treatment 
F or this item the PROCARE Workgroup selected five quality indicators: (a) proportion of 
(y)pStage III patients with R0 resection that received adjuvant chemotherapy within 3 
months after surgery, (b) proportion of pStage II-III patients with R0 resection that received 
adjuvant radiotherapy or chemoradiotherapy within 3 months after surgery, (c) proportion 
of (y)pStage II-III patients with R0 resection that started adjuvant chemotherapy within 12 
weeks after surgical resection, (d) proportion of (y)pStage II-III patients with R0 resection 
treated with adjuvant chemo(radio)therapy, that received 5-FU based chemotherapy and (e) 
rate of acute grade 4 chemotherapy-related complications. 
The rationale for early adjuvant therapy is that it is able to treat micrometastatic disease at a 
time when tumour burden is at a minimum. 5-FU given by intravenous injection for 5 days 
every 4 weeks for 6 cycles is the regimen for which the most evidence is available and that is 
clearly effective in prolonging survival in patients with stage III (18). Treatment with 
chemotherapy is associated with an acceptable complication rate. However, the occurrence 
of complication is dose-dependent and can be kept low artificially by lowering the dose. 
Palliative treatment 
The proportion of cStage IV patients receiving chemotherapy is the only quality indicator 
that was retained in this setting. The aim of palliative systemic therapy is to improve survival 
and quality of live in patients with metastatic disease (18). 
Follow-up 
In this domain, the rate of curatively treated patients that received a colonoscopy within 1 
year after resection, and late grade 4 complications of radiotherapy or chemoradiation were 
selected. 
For curatively treated patients it is recommended to perform a colonoscopy within 1 year 
after resection; the aim is to detect local recurrence at an early potentially (surgically) 
curable stage, and to detect new primary tumours (18,26). 
Histopathologic examination 
The list of quality indicators in the domain of histopathologic examination includes (a) the 
use of a specific pathology report sheet, (b) the quality of TME according to Quirke (38,39) 
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mentioned in the pathology report, (c) the distal tumour-free margin mentioned in the 
pathology report, (d) the number of lymph nodes examined, (e) the (y)pCRM mentioned in 
mm in the pathology report, and (f) the tumour regression grade (40) mentioned in the 
pathology report (after neoadjuvant treatment). 
The quality of TME according to Quirke, the harvested lymph nodes and the status of the 
circumferential resection margin illustrate the quality of TME and affect the patient’s 
oncological outcome (38,41-44). The pathologist should find as many lymph nodes as 
possible. The median number found is an indication of the quality of the pathological 
examination. According to the current TNM guidelines at least 12 lymph nodes need to be 
examined in rectal cancer specimens (45), but higher numbers are desirable and achievable 
in most cases, even after preoperative radiotherapy (46). Examining greater number of 
nodes increases the likelihood of proper staging (47). Yields will vary in relation to many 
factors; they can, however, be maximised through high-quality surgery and diligent 
pathological examination (48). Examination of 6 or fewer lymph nodes is related to poor 
prognosis (49). Best practice demands the reporting of CRM by radiologists and pathologists 
alike (28,29,38). Grading of tumour regression is important since outcome is better in case of 
complete regression than in case of residual microscopic disease which, in turn, is associated 
with better prognosis than cases without or with only minor regression (40,50-52). 
CONCLUSIONS AND PROSPECTS 
Patients deserve consistent standards regardless of where they live or are treated. The 
pursuit of excellence requires the definition of standards and the search is on to find what 
parameters best guarantee equal patient outcome and care. 
Based on literature search and expert opinions, the PROCARE Workgroup has identified a set 
of quality of care indicators (summarised in the table) covering all aspects of the 
management of rectal cancer. Ideally population-based audit should be risk-adjusted; such 
approach requires intensive collaboration between clinicians and statisticians. In order to 
provide teams with simple, userfriendly but relevant feedback information, it might be 
useful to construct one quality index for the outcome (aggregating e.g. overall survival, 
proportion of R0 resections and postoperative major surgical morbidity with reintervention 
under narcosis after radical surgical resection) and one quality index for the process of 
treating rectal cancer (with e.g. time between first histopathological diagnosis and first 
treatment, proportion of APR and Hartmann’s procedure or total excision of colon and 
rectum with definitive ileostomy, and number of lymph nodes examined).  
In addition to national benchmarking, i.e. comparing results from individual hospitals or 
teams with national performances with feedback to participating teams, we should also aim 
for international benchmarking. This comparison could indicate whether further 
improvement is possible and/or warranted. 
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GENERAL QUALITY INDICATORS 
Overall survival by stage 
Disease-specific survival by stage 
Disease-free survival 
Relative survival 
Proportion of patients with local recurrence 
DIAGNOSIS AND STAGING 
Proportion of patients with a documented distance from the anal verge 
Proportion of patients with abdominal CT and thoracal X-ray or CT before any treatment 
Proportion of patients in whom a CEA was performed before any treatment 
Proportion of patients with complete large bowel-imaging before elective surgery 
Proportion of patients with TRUS and pelvic CT and/or pelvic MRI before any treatment 
Proportion of patients with cStage II-III rectal cancer that have a reported cCRM 
Time between first histopathologic diagnosis and first treatment 
Accuracy of cM0 staging 
Accuracy of cT/cN staging in case of no or short radiotherapy 
Use of TRUS in cT1/cT2 stages 
Use of MRI in cStage II or III 
NEOADJUVANT TREATMENT 
Proportion of cStage I patients that received neoadjuvant radio(chemo)therapy 
Proportion of cStage II-III patients that received a neoadjuvant pelvic radiotherapy 
Proportion of cStage II-III patients with neoadjuvant chemoradiation that received a continuous 5-FU infusion 
Proportion of patients completing long course neoadjuvant pelvic RT or chemoradiation within planned timing 
Proportion of patients operated 4 to 12 weeks after completion of long course pelvic RT or chemoradiation 
Proportion of patients with cCRM < or = 2mm that received long course neoadjuvant radio(chemo)therapy 
Rate of acute grade 4 radio(chemo)therapy-related complications 
SURGERY 
Proportion of R0 resections 
(y)p distal margin involved (positive) after SSO or Hartmann’s procedure for low rectal cancer (< or = 5cm) 
Mesorectal (y)pCRM positivity after radical surgical resection 
Poportion of APR, Hartmann’s procedure or proctocolectomy with definitive ileostomy 
Proportion of patients with stoma 1 year after sphincter-sparing surgery 
Major leakage after partial mesorectal excision + SSO + reconstruction 
Major leakage after TME + SSO + reconstruction (global, i.e. with our without primary derivative stoma) 
Inpatient or 30-day mortality 
Rate of intra-operative rectal perforation 
Postoperative major surgical morbidity requiring reintervention under narcosis after radical surgical resection 
ADJUVANT TREATMENT 
Proportion of (y)pStage III patients with R0 resection receiving adjuvant chemotherapy within 3 months 
Proportion of pStage II-III patients with R0 resection receiving adjuvant (chemo)radiotherapy within 3 months 
Proportion of (y)pStage II-III patients with R0 resection that started adjuvant chemotherapy within 12 weeks 
Proportion of (y)pStage II-III patients with R0 resection treated with adjuvant chemotherapy receiving 5-FU 
Rate of acute grade 4 chemotherapy-related complications 
PALLIATIVE TREATMENT 
Proportion of cStage IV patients receiving chemotherapy  
FOLLOW-UP 
Rate of curatively treated patients that received a colonoscopy within 1 year after resection 
Late grade 4 complications of radiotherapy or chemoradiation 
HISTOPATHOLOGIC EXAMINATION 
Use of a specific pathology report sheet 
Quality of TME according to Quirke mentioned in the pathology report 
Distal tumour-free margin mentioned in the pathology report 
Number of lymph nodes examined 
(y)pCRM mentioned in mm in the pathology report 
Tumour regression grade mentioned in the pathology report 
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